Our Expert Network

1. How Informal FDA Feedback Is Quietly Driving RNA Capital Allocation 3/19/2026

   Subtle FDA signals — especially in pre-IND talks — are quietly shaping RNA investment. Early regulatory feedback on CMC and comparability now drives how investors assess risk and allocate capital.

2. From Pandemic Collaboration To Patent Litigation: BioNTech's Case Against Moderna 3/17/2026

   BioNTech’s new lawsuit against Moderna highlights the intensifying post-COVID mRNA patent wars, as companies clash over vaccine design, delivery technologies, and the future of RNA therapeutics.

3. Inside The mRNA–LNP Patent Wars: A Q&A With Goodwin On Litigation, Strategy, And What Comes Next 3/16/2026

   Patent disputes around mRNA constructs and LNP delivery are intensifying. Goodwin’s Natasha Daughtrey and Bill Christiansen unpack litigation trends, IP strategy, and what RNA developers should expect next.

4. MicroRNA Therapeutics In Metabolic Liver Disease: Context-Driven Drug Discovery 3/12/2026

   Realizing the therapeutic potential of miRNAs in liver disease requires confronting a problem the field has not fully reckoned with.

5. Dual Centrifugation And The Next Phase Of Lipid Nanoparticle Development 3/9/2026

   Dual centrifugation enables rapid, small-scale LNP screening with high encapsulation, reproducibility, and preserved RNA integrity — offering a flexible bridge between benchtop discovery and scalable manufacturing.

6. The FDA Plausible Mechanism Framework Just Changed Rare Disease Drug Development 3/9/2026

   Discover how the new FDA Plausible Mechanism Framework changes the game for rare disease research by formalizing an approval pathway for individualized treatment of ultra-rare genetic diseases.

7. The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To Nephrology 3/6/2026

   Nanomedicines are solving the drug delivery problem in kidney disease. The next step: bridging the translational gap to advance these technologies into the clinic.

8. Proteomics Tools: A Resurrection 3/4/2026

   For decades, the evolution of proteomics has lagged. Now, a resurrection is underway. New tools are dismantling limitations, signifying a maturation of systems biology.

9. Engineering Translation: How tRNA Therapeutics Expand The RNA Toolkit 3/3/2026

   Engineered tRNAs target translation itself — correcting shared errors like premature stop codons at the ribosome — to restore functional protein and redefine precision medicine by mechanism, not diagnosis.

10. Microneedle Delivery Of Telomerase Protects Skin From Radiation-Induced DNA Damage 3/2/2026

    Pre-treatment with telomerase mRNA shields human skin from radiation-induced DNA damage, reducing radiotherapy side effects.